NEO vs XLI
NeoGenomics Inc (NEO) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
NeoGenomics Inc (NEO) is a diagnostics & research company listed on US.
XLI (XLI) common stock.
Latest reported NEO revenue for 2026-06-30 was $388.3M. Net income was -$14.9M. NEO currently screens at market cap $924.0M.
XLI does not have a complete income-statement cache yet.
NEO currently screens at market cap $924.0M. XLI currently screens at market cap $0.
Not investment advice. Open the NEO and XLI stock pages for the full models.
Not investment advice.